“Prospective Real-Life Multicenter Study of Tildrakizumab 200 Mg for Moderate-to-Severe Psoriasis: Who Is the Ideal Patient?”. 2024. Dermatology Practical & Conceptual 14 (4): e2024284. https://doi.org/10.5826/dpc.1404a284.